| Date Filed | Type | Description |
| 08/10/2015 |
SC 13G/A
| KCG AMERICAS LLC reports a 13.7% stake in Accentia Biopharmaceuticals, Inc. |
| 02/09/2015 |
SC 13G
| KCG AMERICAS LLC reports a 7% stake in Accentia Biopharmaceuticals, Inc. |
| 11/12/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/15/2013 |
8-K
| Quarterly results |
| 03/07/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/22/2013 |
4
| ACCENTIA BIOPHARMACEUTICALS INC (10% Owner) has filed a Form 4 on BIOVEST INTERNATIONAL INC |
| 02/22/2013 |
RW
| Form RW - Registration Withdrawal Request |
| 02/22/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2013 |
10-Q
| Quarterly Report for the period ended December 31, 2012 |
| 12/26/2012 |
10-K
| Annual Report for the period ended September 30, 2012 |
| 11/23/2012 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 10/26/2012 |
4
| ODONNELL FRANCIS E JR (EXECUTIVE CHAIRMAN) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC|
Txns:
| Disposed of 500,000 shares
@ $0 |
|
| 10/15/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/14/2012 |
4
| Hasara Garrison J. (Acting CFO) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC |
| 09/14/2012 |
4
| Calder Douglas W (VP Strategic Plan/Cap Markets) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC |
| 09/14/2012 |
4
| Santos Carlos (Sr. VP of Prod Dev/Reg Affairs) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC |
| 09/14/2012 |
4
| DUFFEY SAMUEL S (CEO/PRESIDENT/GENERAL COUNSEL) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC|
Txns:
| Granted 1,465,481 options to buy
@ $0.15, valued at
$219.8k
|
|
| 08/14/2012 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 08/14/2012 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 08/14/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/14/2012 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
Docs:
|
"For further information, please visit: http://www.biovest.com Forward-Looking Statements: Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as “may,” “could,” “would,” “should,” “believe..." |
|
| 07/11/2012 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 06/27/2012 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/21/2012 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 06/07/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Secured Promissory Note, in the original principal amount of $1,500,000 payable by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Common Stock Purchase Warrant, issued by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Security Agreement, by Accentia Biopharmaceuticals, Inc. in favor of Pabeti, Inc",
"Amendment No. 1 to Plan Convertible Promissory Note, between Accentia Biopharmaceuticals, Inc. and Dennis Ryll" |
|
| 06/04/2012 |
4
| ACCENTIA BIOPHARMACEUTICALS INC (10% Owner) has filed a Form 4 on BIOVEST INTERNATIONAL INC |
| 05/15/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 05/01/2012 |
4
| ACCENTIA BIOPHARMACEUTICALS INC (10% Owner) has filed a Form 4 on BIOVEST INTERNATIONAL INC |
| 04/13/2012 |
8-K/A
| Form 8-K - Current report [amend] |
| 03/15/2012 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend] |
| 03/09/2012 |
4
| ACCENTIA BIOPHARMACEUTICALS INC (10% Owner) has filed a Form 4 on BIOVEST INTERNATIONAL INC|
Txns:
| Disposed of 400,000 shares
@ $0.75, valued at
$300k
Disposed of 88,499 shares
@ $0.34, valued at
$30.1k
Disposed of 400,000 shares
@ $0.75, valued at
$300k
Disposed of 57,242 shares
@ $0.58, valued at
$33.2k
|
|
| 03/08/2012 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 03/02/2012 |
4
| Santos Carlos (Chief Science Officer) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC |
| 03/02/2012 |
4
| Calder Douglas W (VP Strategic Plan/Cap Markets) has filed a Form 4 on ACCENTIA BIOPHARMACEUTICALS INC |
|